CRISPR/Cas9-mediated elimination of EGFR significantly inhibits tumor cell growth and activates the mitogen-activated protein kinase (MAPK) (p-ERK1/2) pathway (Liu et al., 2020). Here, EGFR is linked to neoplasm.